PuraPharm (HKSE:01498) Total Liabilities: HK$563.3 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01498 PuraPharm Corporation Ltd HKSE:01498
23 GF Score
Price HK$0.28
GF Value HK$0.51
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PuraPharm Total Liabilities?

PuraPharm HKSE:01498 23 Total Liabilities is HK$563.3 Mil as of Dec. 2025. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review.

PuraPharm's Total Liabilities for the quarter that ended in Dec. 2025 was HK$563.3 Mil.

PuraPharm's quarterly Total Liabilities declined from Dec. 2024 (HK$604.53 Mil) to Jun. 2025 (HK$577.10 Mil) and declined from Jun. 2025 (HK$577.10 Mil) to Dec. 2025 (HK$563.27 Mil).

PuraPharm's annual Total Liabilities declined from Dec. 2023 (HK$690.73 Mil) to Dec. 2024 (HK$604.53 Mil) and declined from Dec. 2024 (HK$604.53 Mil) to Dec. 2025 (HK$563.27 Mil).

PuraPharm Total Liabilities Historical Data

* Premium members only.

The historical data trend for PuraPharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PuraPharm Total Liabilities Chart

PuraPharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 804.31 758.21 690.73 604.53 563.27

PuraPharm Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 690.73 651.26 604.53 577.10 563.27
HKSE:01498
23GF Score
PuraPharm Corporation Ltd HKSE:01498
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PuraPharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PuraPharm's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=479.415+(67.02+4.882
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+11.957)
=563.3

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=693.758-130.484
=563.3

PuraPharm's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=479.415+(67.02+4.882
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+11.957)
=563.3

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=693.758-130.484
=563.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$563.3 Mil mean?
PuraPharm (HKSE:01498) has a Total Liabilities of HK$563.3 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PuraPharm and its competitors.
Is PuraPharm's Total Liabilities too high?
PuraPharm's current Total Liabilities is HK$563.3 Mil. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's Total Liabilities compare to ZTS?
PuraPharm's Total Liabilities of HK$563.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PuraPharm and its competitors. PuraPharm's current Total Liabilities is HK$563.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current Total Liabilities is HK$563.3 Mil. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current Total Liabilities is HK$563.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PuraPharm (HKSE:01498) Overvalued in 2026?

Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued. The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51. GuruFocus considers PuraPharm to be Possible Value Trap.

Key valuation signals for HKSE:01498:

  • Total Liabilities: HK$563.3 Mil
  • GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PuraPharm Business Description

Address Phase One, Unit 201-207, 2nd Floor, Wireless Centre, Hong Kong Science Park, New Territories, Pak Shek Kok, Tai Po, Hong Kong, HKG
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score

Get the complete analysis for HKSE:01498

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.28
Price
HK$0.51
GF Value